We use cookies on this site to enable your digital experience. By continuing to use this site, you are agreeing to our cookie policy. close

Amgen Loses Battle In Anemia War With La Roche

Law360 (July 10, 2006, 12:00 AM EDT) -- Marking another chapter in an epic battle over the multi-billion dollar market for anemia treatments, an judge with the International Trade Commission has rejected Amgen Inc.'s bid to bar rival drugmaker Hoffman-La Roche Inc.’s U.S. importation of peg-EPO.

But the ITC’s ruling doesn’t give Hoffman-La Roche (Roche) a green light to manufacture and sell their anti-anemia drug CERA in the U.S. The ruling only allows Roche to import and use peg-EPO for use in clinical trials.

Amgen was quick to point out that the ITC’s decision...
To view the full article, register now.